<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xia X</submitter><funding>Innovation team of general Universities in Guangdong Province</funding><funding>Guangdong Basic and Applied Basic Research Foundation</funding><funding>Science and Technology Program of Guangzhou</funding><funding>National Natural Science Foundation of China</funding><pagination>211</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12659323</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>HER2-positive breast cancer is a prevalent pathological subtype of breast cancer. Resistance to anti-HER2 targeted therapies remains a significant challenge in treatment. Understanding the role of HER2 in breast cancer progression is essential.&lt;h4>Methods&lt;/h4>The proteomics analysis was used to explore the regulated proteins in patients with HER2-positive breast cancer. MTS, EdU staininig, flow cytometry and colony formation assays were used to cell proliferation and apoptosis. Protein expressions and interaction of CAND1 and HER2 were clarified by western blot, immunofluorescence and co-immunoprecipitation experiments. In vivo studies using nude mice demonstrated the role of CAND1 in HER2-positive breast cancer cell growth.&lt;h4>Results&lt;/h4>An increase in CAND1 expression</pubmed_abstract><journal>Breast cancer research : BCR</journal><pubmed_title>CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression.</pubmed_title><pmcid>PMC12659323</pmcid><funding_grant_id>2022KCXTD021</funding_grant_id><funding_grant_id>82373327, 8240111911, 82403028</funding_grant_id><funding_grant_id>2023A03J0427</funding_grant_id><funding_grant_id>2021A1515110868</funding_grant_id><pubmed_authors>Xia X</pubmed_authors><pubmed_authors>Liao Y</pubmed_authors><pubmed_authors>Tang M</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>He X</pubmed_authors><pubmed_authors>Huang H</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression.</name><description>&lt;h4>Background&lt;/h4>HER2-positive breast cancer is a prevalent pathological subtype of breast cancer. Resistance to anti-HER2 targeted therapies remains a significant challenge in treatment. Understanding the role of HER2 in breast cancer progression is essential.&lt;h4>Methods&lt;/h4>The proteomics analysis was used to explore the regulated proteins in patients with HER2-positive breast cancer. MTS, EdU staininig, flow cytometry and colony formation assays were used to cell proliferation and apoptosis. Protein expressions and interaction of CAND1 and HER2 were clarified by western blot, immunofluorescence and co-immunoprecipitation experiments. In vivo studies using nude mice demonstrated the role of CAND1 in HER2-positive breast cancer cell growth.&lt;h4>Results&lt;/h4>An increase in CAND1 expression</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-06T07:09:06.822Z</modification><creation>2026-06-06T03:06:55.529Z</creation></dates><accession>S-EPMC12659323</accession><cross_references><pubmed>41310794</pubmed><doi>10.1186/s13058-025-02158-8</doi></cross_references></HashMap>